Cognitive · Cognitive peptide (research)
BDNF Mimetic
- Drug class
- Cognitive peptide (research)
- Status
- Compounded (503A)
- Also known as
- 7,8-dhf, 7-8-dihydroxyflavone, trkb agonist, bdnf agonist, bdnf peptide
- Reviewed
- 2026-06-01 · Dr. Ana Lisa Carr, MD
What BDNF Mimetic is studied for
- TrkB activation research (research)
- Synaptic plasticity (research)
- Mood and cognition research (research)
Mechanism of action
BDNF Mimetic is being studied in the cognitive category. Small-molecule TrkB activators (7,8-DHF and analogs) studied as BDNF-pathway mimetics. Mechanism of action varies by study model; refer to the kindr clinical library for a deeper writeup.
Frequently asked questions
What is BDNF Mimetic?
BDNF Mimetic is a cognitive peptide. Small-molecule TrkB activators (7,8-DHF and analogs) studied as BDNF-pathway mimetics.
What is BDNF Mimetic studied for?
Published research has examined BDNF Mimetic for trkb activation research, synaptic plasticity, mood and cognition research. Human clinical evidence varies by indication.
Is BDNF Mimetic FDA-approved?
No. BDNF Mimetic is not FDA-approved for the indications listed. It is available compounded by 503A pharmacies under clinician supervision, or for international research use only on this catalog.
How is BDNF Mimetic used in research?
Protocols vary by study. BDNF Mimetic is typically administered subcutaneously in research settings. No validated human therapeutic dose exists outside FDA-approved indications.
What are the known risks?
Long-term human safety data for BDNF Mimetic is limited. Theoretical risks vary by mechanism. Any human use should be supervised by a licensed clinician.